Cytoreductive Nephrectomy: Assessing the Generalizability of the CARMENA Trial to Real-world National Cancer Data Base Cases
Recommended Citation
Arora S, Sood A, Dalela D, Tang HJ, Patel A, Keeley J, Trinh QD, Rogers CG, Menon M, and Abdollah F. Cytoreductive nephrectomy: Assessing the generalizability of the CARMENA trial to real-world national cancer data base cases. Eur Urol 2018; 75(2):352-353.
Document Type
Article
Publication Date
2-1-2019
Publication Title
European urology
Keywords
Adult, Aged, Aged, 80 and over, Antineoplastic Agents/adverse effects/therapeutic use, Carcinoma, Renal Cell/mortality/secondary/therapy, Chemotherapy, Adjuvant, Clinical Trials, Phase III as Topic/methods, Cytoreduction Surgical Procedures/adverse effects/mortality, Databases, Factual, Female, Humans, Kidney Neoplasms/mortality/pathology/therapy, Male, Middle Aged, Multicenter Studies as Topic/methods, Nephrectomy/adverse effects/mortality, Research Design, Retrospective Studies, Sunitinib/adverse effects/therapeutic use, Time Factors, Treatment Outcome
Medical Subject Headings
Adult; Aged; Aged; 80 and over; Antineoplastic Agents/adverse effects/therapeutic use; Carcinoma; Renal Cell/mortality/secondary/therapy; Chemotherapy; Adjuvant; Clinical Trials; Phase III as Topic/methods; Cytoreduction Surgical Procedures/adverse effects/mortality; Databases; Factual; Female; Humans; Kidney Neoplasms/mortality/pathology/therapy; Male; Middle Aged; Multicenter Studies as Topic/methods; Nephrectomy/adverse effects/mortality; Research Design; Retrospective Studies; Sunitinib/adverse effects/therapeutic use; Time Factors; Treatment Outcome
PubMed ID
30420256
Volume
75
Issue
2
First Page
352
Last Page
353
